Skip to Content

MabCure Inc MBCI

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

MabCure Inc is engaged in the business of developing and commercializing its proprietary antibody technology for the early detection of cancer and for the creation of specific therapeutics against cancer.

Contact
275 Palm Beach Drive, Suite No. 15740
New York, NY, 10003
T +1 845 591-3144
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2011
Fiscal Year End Dec 31, 2012
Stock Type
Employees 3